Exelixis, Inc. - Product Pipeline Review - 2014

Published: May, 2014 | Pages: 48 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Exelixis, Inc. - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Exelixis, Inc. - Product Pipeline Review - 2014', provides an overview of the Exelixis, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Exelixis, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Exelixis, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Exelixis, Inc.'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Exelixis, Inc.'s pipeline products

Reasons to buy

- Evaluate Exelixis, Inc.'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Exelixis, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Exelixis, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Exelixis, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Exelixis, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Exelixis, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Exelixis, Inc. Snapshot 5
Exelixis, Inc. Overview 5
Key Information 5
Key Facts 5
Exelixis, Inc. - Research and Development Overview 6
Key Therapeutic Areas 6
Exelixis, Inc. - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
Pipeline Products - Out-Licensed Products 11
Out-Licensed Products/Combination Treatment Modalities 12
Exelixis, Inc. - Pipeline Products Glance 13
Exelixis, Inc. - Late Stage Pipeline Products 13
Phase III Products/Combination Treatment Modalities 13
Exelixis, Inc. - Clinical Stage Pipeline Products 14
Phase II Products/Combination Treatment Modalities 14
Phase I Products/Combination Treatment Modalities 15
Exelixis, Inc. - Early Stage Pipeline Products 16
Preclinical Products/Combination Treatment Modalities 16
Exelixis, Inc. - Drug Profiles 17
cabozantinib s-malate 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
XL-888 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
Small Molecules to Agonize S1P1R for Autoimmune Diseases 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
XL-541 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
Exelixis, Inc. - Pipeline Analysis 23
Exelixis, Inc. - Pipeline Products by Target 23
Exelixis, Inc. - Pipeline Products by Route of Administration 25
Exelixis, Inc. - Pipeline Products by Molecule Type 26
Exelixis, Inc. - Pipeline Products by Mechanism of Action 27
Exelixis, Inc. - Recent Pipeline Updates 29
Exelixis, Inc. - Dormant Projects 42
Exelixis, Inc. - Discontinued Pipeline Products 43
Discontinued Pipeline Product Profiles 43
XL-228 43
XL-281 43
XL-418 43
XL-820 43
XL-844 43
Exelixis, Inc. - Company Statement 44
Exelixis, Inc. - Locations And Subsidiaries 46
Head Office 46
Other Locations & Subsidiaries 46
Appendix 47
Methodology 47
Coverage 47
Secondary Research 47
Primary Research 47
Expert Panel Validation 47
Contact Us 48
Disclaimer 48

List of Tables
Exelixis, Inc., Key Information 5
Exelixis, Inc., Key Facts 5
Exelixis, Inc. - Pipeline by Indication, 2014 7
Exelixis, Inc. - Pipeline by Stage of Development, 2014 9
Exelixis, Inc. - Monotherapy Products in Pipeline, 2014 10
Exelixis, Inc. - Out-Licensed Products in Pipeline, 2014 11
Exelixis, Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2014 12
Exelixis, Inc. - Phase III, 2014 13
Exelixis, Inc. - Phase II, 2014 14
Exelixis, Inc. - Phase I, 2014 15
Exelixis, Inc. - Preclinical, 2014 16
Exelixis, Inc. - Pipeline by Target, 2014 24
Exelixis, Inc. - Pipeline by Route of Administration, 2014 25
Exelixis, Inc. - Pipeline by Molecule Type, 2014 26
Exelixis, Inc. - Pipeline Products by Mechanism of Action, 2014 28
Exelixis, Inc. - Recent Pipeline Updates, 2014 29
Exelixis, Inc. - Dormant Developmental Projects,2014 42
Exelixis, Inc. - Discontinued Pipeline Products, 2014 43
Exelixis, Inc., Subsidiaries 46